Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Dec 10, 2010

Premium

Vermillion this week announced that its stockholders have voted to approve the reappointment of Gail Page, John Hamilton, and William Wallen as directors of the company.

Page, Vermillion's CEO, joined the company in January 2004 and has been a director since 2005. Hamilton has been on the company's board since April 2008. Prior to that he was vice president and chief financial officer of Depomed. Wallen was appointed to the board in February, before which he was a member of the company's scientific advisory board. Previously he was senior vice president and chief scientific officer at Idexx Laboratories.


Martin Madaus has joined the board of directors for array maker Quanterix.

Madaus recently was president, CEO, and chairman for Millipore, and before that he was president and CEO at Roche Diagnostics and vice president of business development for Roche Molecular Diagnostics. He currently is a director of the Massachusetts High Technology Council.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.